Literature DB >> 19637320

Establishment and characterization of a cancer cell line derived from an aggressive childhood liver tumor.

Tina T-L Chen1, Dinesh Rakheja, Jaclyn Y Hung, Peter J Hornsby, Piotr Tabaczewski, Marcio Malogolowkin, James Feusner, Frank Miskevich, Roger Schultz, Gail E Tomlinson.   

Abstract

BACKGROUND: Hepatoblastoma is a rare malignancy of childhood. The scarcity of adequate cell models has limited our understanding of this tumor. Here we describe and characterize a new human liver tumor cell line, Hep293TT, derived from an aggressive childhood hepatoblastoma. PROCEDURES: Hep293TT cells were established using primary tumor tissues from a 5-year-old Caucasian female child. This cell line has been maintained for more than 34 months and over 20 subcultures, and was characterized by histopathology, ELISA, genotype, cytogenetics, CGH array, immunohistochemistry, and molecular sequence analyses.
RESULTS: Cells were confirmed to originate from parental tumor cells, secrete alpha-fetoprotein, and express hepatic markers and beta-catenin. Hep293TT cells were able to form colonies in soft agar. Tumorigenicity was demonstrated by induction of solid tumors after subrenal capsule injection in immunodeficient mice. Hep293TT cells demonstrated a highly aneuploid karyotype, and a whole genome CGH analysis revealed chromosomal imbalances in every chromosome. Allelotype analysis demonstrated loss of alleles at distal 11p15.5 as is typical of embryonal tumors. Both Hep293TT cells and the primary tumor contain a deletion of 351 nucleotides in beta-catenin, as has been seen in other hepatoblastoma tumors. The cell line expressed beta-catenin protein in both full-length and partially deleted forms, and expressed NOTCH2 protein characteristic of hepatoblasts. No mutation was detected in the APC, MYH, MLH1, or MSH2 genes.
CONCLUSION: This cell line, Hep293TT, is a valuable resource for the study of childhood liver cancer and may potentially provide a tool in the development of new agents.

Entities:  

Mesh:

Year:  2009        PMID: 19637320     DOI: 10.1002/pbc.22187

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  16 in total

1.  Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin.

Authors:  Sarah A Comerford; Elizabeth A Hinnant; Yidong Chen; Hima Bansal; Shawn Klapproth; Dinesh Rakheja; Milton J Finegold; Dolores Lopez-Terrada; Kathryn A O'Donnell; Gail E Tomlinson; Robert E Hammer
Journal:  JCI Insight       Date:  2016-10-06

2.  Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation.

Authors:  Yuan Wang; Chen Ling; Liujiang Song; Lina Wang; George V Aslanidi; Mengqun Tan; Changquan Ling; Arun Srivastava
Journal:  Hum Gene Ther Methods       Date:  2012-08       Impact factor: 2.396

3.  Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3.

Authors:  Chen Ling; Yuan Lu; Jasmine K Kalsi; Giridhara R Jayandharan; Baozheng Li; Wenqin Ma; Binbin Cheng; Samantha W Y Gee; Katherine E McGoogan; Lakshmanan Govindasamy; Li Zhong; Mavis Agbandje-McKenna; Arun Srivastava
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

4.  TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma.

Authors:  Jie Zhang; Pin Liu; Junyan Tao; Pan Wang; Yi Zhang; Xinhua Song; Li Che; Pavel Sumazin; Silvia Ribback; Andras Kiss; Zsuzsa Schaff; Antonio Cigliano; Frank Dombrowski; Carla Cossu; Rosa M Pascale; Diego F Calvisi; Satdarshan P Monga; Xin Chen
Journal:  Am J Pathol       Date:  2019-02-19       Impact factor: 4.307

5.  Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.

Authors:  Beatrice Bissig-Choisat; Claudia Kettlun-Leyton; Xavier D Legras; Barry Zorman; Mercedes Barzi; Leon L Chen; Mansi D Amin; Yung-Hsin Huang; Robia G Pautler; Oliver A Hampton; Masand M Prakash; Diane Yang; Malgorzata Borowiak; Donna Muzny; Harsha Vardhan Doddapaneni; Jianhong Hu; Yan Shi; M Waleed Gaber; M John Hicks; Patrick A Thompson; Yiling Lu; Gordon B Mills; Milton Finegold; John A Goss; D Williams Parsons; Sanjeev A Vasudevan; Pavel Sumazin; Dolores López-Terrada; Karl-Dimiter Bissig
Journal:  J Hepatol       Date:  2016-04-23       Impact factor: 25.083

6.  CITED1 expression in liver development and hepatoblastoma.

Authors:  Andrew J Murphy; Christian de Caestecker; Janene Pierce; Scott C Boyle; Gregory D Ayers; Zhiguo Zhao; Jaime M Libes; Hernan Correa; Teagan Walter; Stacey S Huppert; Alan O Perantoni; Mark P de Caestecker; Harold N Lovvorn
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

7.  Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells.

Authors:  B Cheng; C Ling; Y Dai; Y Lu; L G Glushakova; S W Y Gee; K E McGoogan; G V Aslanidi; M Park; P W Stacpoole; D Siemann; C Liu; A Srivastava; C Ling
Journal:  Gene Ther       Date:  2011-07-21       Impact factor: 5.250

8.  High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors.

Authors:  Chen Ling; Yuan Lu; Binbin Cheng; Katherine E McGoogan; Samantha W Y Gee; Wenqin Ma; Baozheng Li; George V Aslanidi; Arun Srivastava
Journal:  J Vis Exp       Date:  2011-03-22       Impact factor: 1.355

9.  Might salicylate exert benefits against childhood cancer?

Authors:  G Morgan; Ji Johnsen
Journal:  Ecancermedicalscience       Date:  2010-01-19

10.  De-regulated microRNAs in pediatric cancer stem cells target pathways involved in cell proliferation, cell cycle and development.

Authors:  Patricia C Sanchez-Diaz; Tzu-Hung Hsiao; Judy C Chang; Dong Yue; Mimi C Tan; Hung-I Harry Chen; Gail E Tomlinson; Yufei Huang; Yidong Chen; Jaclyn Y Hung
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.